A prospective study tested PANXEON, an exosome-based blood biomarker, in 1,785 individuals recruited across four countries. The biomarker was assessed in combination with carbohydrate antigen 19-9. The combination achieved high sensitivity for the detection of early-stage pancreatic cancer.
Why it is interesting: Prospective evidence, across four countries, on detecting pancreatic cancer early from a blood sample.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.